Xarelto (rivaroxaban), a Factor Xa inhibitor, has recently been approved by the FDA for the treatment of Deep Vein Thrombosis. A recent trial has also shown that Xarelto is noninferior to Coumadin (warfarin) in treatment for Atrial Fibrillation. The following article discusses studies involving this new and exciting medication. http://www.internalmedicinenews.com/newsletter/internal-medicine-news-e-newsletter/singleview40766/rivaroxaban-contests-warfarin-for-stroke-prevention-in-af/cb1b135f01.html
March 1, 2024
No Comments
